title: Late Reactivation of Hepatitis B Virus after Chemotherapies for Hematological Malignancies: A Case Report and Review of the Literature.
abstract: Reactivation of hepatitis B virus (HBV) is a serious complication of immunosuppressive therapy and cytotoxic chemotherapy. The optimal duration of HBV-DNA monitoring for at-risk patients depends on the clinical features of reactivation, especially the range of potency from therapies to reactivation. We present a case of very late reactivation after chemotherapy for lymphoma and review previous reports of late reactivation cases. We also underscore the significance of developing an indicator for anti-HBV immunity which can be used to determine the optimal monitoring period.
authors.affiliation: Department of Hematology, Gifu Prefectural Medical Center, Japan.
authors.forename: Toshiki
authors.initials: T
authors.lastname: Yamada
authors.forename: Yasuhito
authors.initials: Y
authors.lastname: Nannya
authors.forename: Atsushi
authors.initials: A
authors.lastname: Suetsugu
authors.forename: Shogo
authors.initials: S
authors.lastname: Shimizu
authors.forename: Junichi
authors.initials: J
authors.lastname: Sugihara
authors.forename: Masahito
authors.initials: M
authors.lastname: Shimizu
authors.forename: Mitsuru
authors.initials: M
authors.lastname: Seishima
authors.forename: Hisashi
authors.initials: H
authors.lastname: Tsurumi
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D019337:Hematologic Neoplasms / Q000188:drug therapy*; D006509:Hepatitis B / Q000188:drug therapy / Q000209:etiology*; D006514:Hepatitis B Surface Antigens / Q000097:blood; D006515:Hepatitis B virus / Q000472:pathogenicity*; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy*; D008297:Male; D014775:Virus Activation / Q000187:drug effects*
chemical_list: D000970:Antineoplastic Agents; D006514:Hepatitis B Surface Antigens